Filing Details

Accession Number:
0001144204-15-037760
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-06-17 20:28:03
Reporting Period:
2015-06-15
Filing Date:
2015-06-17
Accepted Time:
2015-06-17 20:28:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1574235 Pulmatrix Inc. PULM Pharmaceutical Preparations (2834) 461821392
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1644981 David Maki C/O Pulmatrix, Inc
990 Hayden Ave
Lexington MA 02421
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-06-15 181,819 $0.00 181,819 No 4 A Indirect See Footnote
Common Stock Acquisiton 2015-06-16 36,375 $6.88 218,194 No 4 P Indirect See Footnote
Common Stock Acquisiton 2015-06-15 181,819 $0.00 181,819 No 4 A Indirect See Footnote
Common Stock Acquisiton 2015-06-16 36,375 $6.88 218,194 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Indirect See Footnote
No 4 P Indirect See Footnote
No 4 A Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants to Purchase Common Stock Acquisiton 2015-06-15 398,754 $0.00 398,754 $7.56
Common Stock Warrants to Purchase Common Stock Acquisiton 2015-06-15 398,754 $0.00 398,754 $7.56
Common Stock Stock Option (Right to Buy) Acquisiton 2015-06-15 1,186 $0.00 1,186 $2.20
Common Stock Stock Option (Right to Buy) Acquisiton 2015-06-15 14,850 $0.00 14,850 $2.20
Common Stock Stock Option (Right to Buy) Acquisiton 2015-06-15 1,186 $0.00 1,186 $2.20
Common Stock Stock Option (Right to Buy) Acquisiton 2015-06-16 12,720 $0.00 12,720 $11.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
398,754 No 4 A Indirect
398,754 No 4 A Indirect
1,186 2019-12-09 No 4 A Direct
14,850 2020-05-24 No 4 A Direct
1,186 2020-10-05 No 4 A Direct
12,720 2025-06-16 No 4 A Direct
Footnotes
  1. Reflects a 1-for-2.5 reverse stock split effected on June 15, 2015.
  2. On June 15, 2015, Altitude Life Science Ventures Fund II, L.P. ("Altitude Fund II") received these shares of the Issuer's Common Stock in exchange for securities of a private company formerly known as Pulmatrix, Inc. (the "Former Entity") in connection with the merger of the Former Entity into the Issuer (the "Merger").
  3. On June 15, 2015, Altitude Life Science Ventures Side Fund II, L.P. ("Altitude Side Fund II") received these shares of the Issuer's Common Stock in exchange for securities of a private Former Entity in connection with the Merger.
  4. Represents securities directly beneficially owned by Altitude Fund II. Mr. Maki, a director of the Issuer and the General Partner of Altitude Fund II, may be deemed to have beneficially ownership over the shares held by Altitude Fund II. Mr. Maki disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.
  5. Represents securities directly beneficially owned by Altitude Side Fund II. Mr. Maki, a director of the Issuer and the General Partner of Altitude Side Fund II, may be deemed to have beneficially ownership over the shares held by Altitude Side Fund II. Mr. Maki disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.
  6. These warrants are exercisable (the "Initial Exercise Date") upon the earliest to occur of (a) the Issuer entering into a strategic license agreement with a third party related to any of the Issuer's products pursuant to which the Issuer is guaranteed to receive consideration from such third party consisting of cash, marketable securities or a combination thereof having a value of at least $20,000,000 in the aggregate; (b) the Issuer consummating a public or private offering of Common Stock or common stock equivalents resulting in gross proceeds to the Issuer of at least $20,000,000 at a price per share of at least $4.00 per share (subject to adjustment for stock splits, reverse stock splits, stock dividends and other similar events, but no adjustment shall be made in respect of the Merger); (continue on footnote 7)
  7. (continued from footnote 6) (c) the volume weighted average price per share of Common Stock exceeding $5.00 (subject to adjustment for stock splits, reverse stock splits, stock dividends and other similar events, but no adjustment shall be made in respect of the Merger) for a period of sixty consecutive trading days and the average daily trading volume exceeds 100,000 (subject to adjustment for stock splits, reverse stock splits, stock dividends and other similar events, but no adjustment shall be made in respect of the Merger) shares of Common Stock per trading day; or (d) a change of control. These warrants expire five years from the Initial Exercise Date.
  8. On June 15, 2015, Altitude Fund II received these warrants to purchase shares of the Issuer's Common Stock in exchange for warrants to purchase 6,727,184 shares of common stock of Former Entity with an exercise price of $0.448266 in connection with the Merger.
  9. On June 15, 2015, Altitude Side Fund II received these warrants to purchase shares of the Issuer's Common Stock in exchange for warrants to purchase 6,727,184 shares of common stock of Former Entity with an exercise price of $0.448266 in connection with the Merger.
  10. On June 15, 2015, Mr. Maki received these securities of the Issuer in exchange for a stock option to acquire 20,000 shares of common stock of the Former Entity for $0.13 per share, in connection with the Merger.
  11. These options are fully vested and exercisable.
  12. On June 15, 2015, Mr. Maki received these securities of the Issuer in exchange for a stock option to acquire 250,520 shares of common stock of the Former Entity for $0.13 per share, in connection with the Merger.
  13. On June 15, 2015, Mr. Maki received these securities of the Issuer in exchange for a stock option to acquire 20,000 shares of common stock of the Former Entity for $0.13 per share, in connection with the Merger.
  14. The option vests as to 2.08% monthly for 48 months from the date of grant.